Background: Human Papillomavirus (HPV) is tightly associated with the development of cervical dysplasia and carcinoma, and more recently, HPV has been linked to squamous lesions at other sites, especially head and neck. The role of HPV in the development of squamous lesions of the eye is poorly understood and controversial. Here, we retrospectively surveyed squamous lesions identifi ed in ocular biopsies, enucleations, and orbital exenterations performed at our institution and examined them for HPV infection via immunohistochemistry and PCR. Design: The ocular lesions were fi rst evaluated for p16 immunoreactivity since p16 is strongly induced by HPV infection. Cases with strong diffuse positivity for p16 were further assessed for HPV serotype expression by PCR genotyping (ARUP HPV panel). The squamous ocular lesions selected for this study included seborrheic keratoses (SKs), pterygiums, verruca vulgari (VVs), squamous papillomas, achrocordons, conjunctival intraepithelial neoplasms (CIN), and squamous cell carcinomas (SCCs). All lesions were reviewed histologically for additional features, including solar damage and dysplasia. The lesions were further subdivided by patient gender and age and analyzed for trends. Cases reviewed were from The University of California San Diego (UCSD) and VA San Diego Hospital in which tissue specimens were submitted to the eye pathology service. In total, we analyzed approximately 50 seborrheic keratoses, 30 pterygiums, 12 achrocordons, 10 CINs, 10 SCCs, 5 squamous papillomas, and 5 VVs. Results: As of this submission 85% of SKs (11 of 13) tested have shown p16 immunoreactivity; 67% of pterygiums (4 of 6) have been positive; 86% of CINs (6 of 7); 100% of VVs (2 of 2) and 100% of SCCs (4 of 4). There was no clear link between cases that were p16-reactive and clinical demographics including age, gender, and ethnicity in our samples. The ocular squamous lesions further analyzed by HPV PCR genotyping were all negative for high-risk subtypes. Conclusions: Our findings revealed a surprisingly large prevalence of p16 immunoreactivity in nearly all squamous lesions at our institutions. No clear correlation was seen between the p16-positive ocular squamous lesions and patient age or gender or ethnicity. Surprisingly, these lesions were not positive for high-risk HPV variants. Our fi ndings raise the possibility that other HPV variants may be involved in development of ocular squamous lesions. Background: Ocular surface squamous neoplasia (OSSN) encompasses squamous dysplasia (mild-severe,CIN 1-3) and invasive squamous cell carcinoma (SCC) involving the conjunctiva and cornea. A traditionally accepted management modality is widemargin (4-5 mm) excisional biopsy followed by cryotherapy. The conjunctival defect is then closed using conjunctival or amniotic membrane graft. Additional treatment strategies include chemotherapy and immunotherapy either in conjunction with or in lieu of surgery. Removing more tissue than necessary can compromise ocular function, for example by causing limbal cell insuffi ciency. Thus a re-evaluation was deemed warranted. Design: With IRB approval, a retrospective analysis of all patients presenting to one clinician (AS) with clinical OSSN from 2004-2012 requiring surgical excision was conducted. Results: There were 32 cases, two of whom had been treated previously with topical chemotherapy for chemoreduction. All lesions were excised with 1-2mm clinical margins and treated with cryotherapy. The mean follow-up time was 24.4 months (range: 1-84 months). In 17 cases there was corneal involvement. Pathological distribution of the lesions included 25 non-invasive OSSN (1 with CIN1, 5 CIN2, and 19 CIN3 or severe dysplasia/squamous carcinoma in situ) and 7 invasive SCC. 11 cases (34%) had positive pathological margins. At 1-year and 5-year follow-up, only 2 of 32 eyes (6%) had evidence of recurrence, respectively. The cases had SCC in situ and microinvasive SCC; both had positive initial margins. 3 patients in the cohort expired from causes unrelated to ocular disease. Conclusions: OSSN can be managed surgically with adjunct cryotherapy using smaller margins without compromising clinical outcome. This may improve anatomical results and minimize the morbidity of the treatment.
Conclusions:
We conclude that discarded supernatant fl uid, even in ND pancreatic FNA, contains suffi cient DNA for MP. The presence of a mutation may enhance our ability to detect malignancy, particularly when FNA is ND or atypical. Absence of a mutation does not exclude malignancy but with a negative FNA and in the appropriate clinical context, MP can provide additional information to guide clinical management. S Balci, P Bagci, N Dursun, K-T Jang, B Saka, N Ohike, JC Roa, T Tajiri, C Moreno, M Rossi, J Xu, R Hruban, H Matthaei, K Fisher, P Terry, V Adsay . EU, Atlanta, GA; SMC, Seoul, Korea; SU, Tokyo, Japan; PUC, Santiago, Chile; TU, Tokyo, Japan; JHU, Baltimore, MD; UB, Bonn, Germany; UT, Knoxville, TN. Background: Preinvasive (adenomatous/papillary) lesions of the gallbladder, >1cm (intracholecystic papillary tubular neoplasms; ICPNs), composed of small, nonmucinous tubules with complex architecture is a poorly characterized group.
Complex Tubular Type Intracholecystic Papillary Tubular Neoplasms (ICPN): Further Clinicopathologic and Molecular Characterization
Design: Twenty examples were analyzed and contrasted with other GB pathology (Table) . Four examples had been previously reviewed by 18 experts as a part of an international consensus, and all had been assigned a diagnosis of HGD/CIS (mostly "tubular/tubulopapillary carcinoma"). Results: They were pedunculated polyps with thin stalk and nodular growth, and mostly over-lined by normal epithelium (15), with overall architecture of cholesterol polyps. Some (6) also had cholesterol macrophages. Cystic glands with eosinophilic secretions and amorphous stromal hyalinization (5), morules (13), nuclei resembling papillary thyroid ca (13) were also seen. All revealed HGD (<25% of the tumor in 3; 25-75% in 8, and >75% in 9). Uninvolved GB was devoid of any pathology, except 1 showing focal dysplasia. None had invasive carcinoma. Diffuse MUC6 staining seen (pyloric differentiation) in all, and focal MUC1 in 69% (in high-grade areas); none had diffuse MUC2/CDX2. RNA sequencing performed in 4 revealed activation of various cancer related/cell movement gene groups. 
Conclusions:
ICPNs with complex tubular pattern of non-mucinous cells form a clinicopathologically distinct subset with a propensity to occur in men, in GBs without injury, and show association with cholesterol polyps. Although there is overt cyto-architectural complexity (HGD) , and molecular analysis also shows activation of cancer related pathways; they seem to have virtually no ability to become invasive unlike other ICPNs. S Balci, B Saka, P Bagci, K-T Jang, A Krasinskas, G Kim, N Ohike, T Tajiri, O Basturk, N Dursun, N Zarrabi, J Knight, V Adsay . Emory, Atlanta, GA; SMC, Seoul, Korea; UCSF, San Francisco, CA; SU, Tokyo, Shinagawa, Japan; TU, Tokyo, Hiratsuka, Japan; MSKCC, NY, NY. Background: Medullary carcinomas (MC) are now recognized as a distinct type of carcinoma in the GI tract. There is virtually no data on the frequency or clinicopathologic characteristics of the ampullary counterparts of these tumors. Design: 359 ampullary carcinomas (AC) were analyzed. Non-ampullary duodenal as well as pancreatic and distal CBD carcinomas were carefully excluded. Results: Eleven cases fulfi lled the criteria for MC (3.2% of ACs). MCs occurred in younger patients than other ACs (mean age, 57 vs 65; p=0.03), and more commonly in males (M/F = 9/2 vs 197/144; p=0.13). Size of invasive carcinoma was larger than that of other ACs (mean, 27.5 vs 18.5 mm; p=0.01). Four (40%) had positive lymph nodes (vs 46%). In addition to classical medullary pattern (syncytial growth, pushingborder infi ltration and peritumoral infl ammation), 8 cases showed abortive gland-like formations within the syncytial nodules, and one also showed focal signet ring cells. Nine had separate minor mixed component of other carcinoma patterns: mucinous in 6; tubular in 4 (tubular-intestinal 1, tubular-pancreatobiliary 3); squamoid in 2; poorly differentiated, NOS in 2; acinar-like in 1; rhabdoid in 1. None revealed loss of INI-1 by immunohistochemistry. Preinvasive (adenomatous) component was either absent (8 cases) or if present (3 cases; intestinal in 2, gastric-pancreatobiliary in 1), it was minimal in amount except for one case. Six had abundant intratumoral neutrophil infi ltration and 4 had prominent eosinophils. As for site-specifi c origin in the ampulla, 8 tumors were AMP-NOS (papilla of Vater origin), 2 were AMP-duodenal (arising from the duodenal surface of the ampulla), and 1 was associated with intraampullary papillary-tubular neoplasm. MCs were strongly associated with microsatellite instability, with 7/8 cases revealing loss of MMR proteins by immunohistochemistry (vs 11/86 non-medullary ACs; p< 0.001). Of these 7 cases, 6 had MLH1 and PMS2 losses, and 1 had MSH2 loss. Although the 3-yr and 5-yr survival rates of 67% and 67% appeared to be higher than those of other ACs (61% and 47%), the difference did not reach statistical signifi cance (p=0.47).
Medullary Carcinomas of the Ampulla: Clinicopathologic Analysis of 11 Cases

Conclusions:
Medullary carcinomas constitute 3% of ACs. They occur predominantly in males, and in slightly younger age group. They are closely associated with microsatellite instability. Despite their large size and poorly differentiated appearance, their clinical behavior appears to be similar, if not better, than that of other ACs.
Pitfalls of Frozen Ssction Interpretation for Pancreatectoy after
Neoadjuvant Therapy AL Barbieri, S Tsai, DB Evans, K Oshima. Medical College of Wisconsin, Milwaukee, WI. Background: Neoadjuvant chemoradiation therapy (NCRT) followed by pancreatectomy has been increasingly used in the treatment of pancreatic adenocarcinoma. Frozen sections play an important role in achieving complete resection in these cases. Our institution has a high volume of NCRT pancreatic resections and we are frequently faced with evaluating the margin status intraoperatively; potential pitfalls in the interpretation of these challenging specimens have not been previously described. Design: We retrospectively reviewed the frozen section and permanent slides from 145 patients who completed NCRT and underwent pancreatic resection at our institution from 2009 to 2013; thirty-six patients who underwent pancreatectomy without neoadjuvant treatment were used as the control group. Frozen section diagnoses and fi nal permanent diagnoses were recorded. Frequency and causes of discrepancy were analyzed. Results: Three hundred and twenty-fi ve frozen sections (183 pancreatic margins and 142 bile duct margins) were reviewed. Major discrepancies were seen in 8 cases within the NCRT group (5 false negatives and 3 false positives). All of the fi ve false negative discrepancies occurred at the pancreatic margin and there were no false negatives at the bile duct margin. False positives were seen in both the pancreatic (2) and bile duct (1) margins. A single false positive was identifi ed in the control group and there were no false negatives. Our preliminary data suggests that false negatives are a more frequent concern in the NCRT group. Based on our review, the NCRT tumors are inconspicuous and malignant cells are present in a diffusely fi brotic stroma without the focal stromal reaction is helpful in the evaluation of non-NCRT cases. Tumors can also be discontinuous after NCRT with positive margins despite a more prominent distant focus. We have also seen invasive carcinoma that can mimic PanIN. Conclusions: Frozen section interpretation after NCRT is challenging, and the false negative rate is higher than the control group. Pathologists should be aware of the pitfalls after NCRT to improve precision and accuracy. TL Bartholow, RK Pai, JA Kant, HJ Zeh, KK Lee, M Wijkstrom, D Yadav, RE Brand, JS Chennat, ME Lowe, GI Papachristou, A Slivka, DC Whitcomb, A Humar, AD Singhi. UPMC, Pittsburgh, PA. Background: Hereditary pancreatitis is an autosomal dominant disorder with 80% penetrance and variable expressivity. The vast majority of cases have been linked to mutations within the cationic trypsinogen gene, also referred to as serine protease 1 (PRSS1). Other than inheritance, PRSS1 pancreatitis has been considered clinically and pathologically indistinguishable from other etiologies of chronic pancreatitis. However, to date, the histologic fi ndings of PRSS1 pancreatitis have not been well-described.
The Histopathology of PRSS1 Hereditary Pancreatitis
Design:
We collected pancreatic specimens from 10 PRSS1 patients of various ages and examined their clinicopathologic features. In addition, we compared these fi ndings with more common etiologies of chronic pancreatitis including alcohol-associated and obstructive chronic pancreatitis.
Results:
Patients at the time of resection ranged in age from 9 to 66 years (median, 29 years) with a slight female predominance (60%). All patients reported a history of intermittent abdominal pain with an age of onset ranging from infancy to 21 years of age. Examination of the gross and microscopic fi ndings suggested a sequential pattern of changes with increasing patient age. In pediatric patients (n = 4), although in most cases the pancreas was grossly normal, there was microscopic variation in lobular size and shape. While the central portions of the pancreas displayed parenchymal loss accompanied by loose perilobular and interlobular fi brosis, the periphery was remarkable for replacement by mature adipose tissue. These changes were more developed in younger adults (n = 2), where fatty replacement seemed to extend from the periphery to the central portions of the pancreas. With older patients (n = 4), the pancreas showed marked atrophy and extensive replacement by mature adipose tissue with scattered islets of Langerhans and rare acinar epithelium concentrated near the main pancreatic duct. In comparison, pancreata from patients with alcohol-associated (n = 14) and obstructive (n = 8) chronic pancreatitis also demonstrated marked parenchymal loss, but replacement with prominent fi brosis. Conclusions: In summary, contrary to previous assertions, PRSS1 hereditary pancreatitis is characterized by progressive lipomatous atrophy of the pancreas. As genetic testing for hereditary pancreatitis becomes more widespread, future studies should provide mechanistic insight into this debilitating disease. Design: Pancreatic cyst fl uid DNA obtained by endoscopic ultrasound-fi ne needle aspiration was retrospectively collected from 75 pancreatic cysts that later underwent surgical resection. These cases included 36 IPMNs, 9 adenocarcinomas arising in association with an IPMN, 16 MCNs, 10 cystic pancreatic neuroendocrine tumors, 2 retention cysts, 1 pseudocyst and 1 lymphoepithelial cyst. In addition, 6 cyst fl uid DNA specimens were selected that clinically corresponded to serous cystadenomas based on radiographic imaging, endoscopic ultrasound, CEA level of <2.0 ng/mL and cytopathologic fi ndings. All cases were analyzed for mutations in GNAS (codon 201) and KRAS (codons 12, 13 and 61).
Results: Point mutations in GNAS were detected in 13 of 36 (36%) IPMNs, and 2 of 9 (22%) adenocarcinomas arising in association with an IPMN. KRAS mutations were identifi ed in 24 (67%) IPMNs, 7 (78%) adenocarcinomas, and 1 of 16 (6%) MCNs. Mutations in either gene were present in 29 (89%) IPMNs, 8 (89%) adenocarcinomas, and 1 (6%) MCN. No mutations were found in cyst fl uid from cystic pancreatic neuroendocrine tumors, serous cystadenomas, retention cysts, a pseudocyst and a lymphoepithelial cyst. Overall, GNAS and KRAS mutations had a specifi city of 100%, but a sensitivity of 62% for mucinous differentiation. Among IPMNs, mutations in either gene had a specifi city and sensitivity of 97% and 82%, respectively. Conclusions: In summary, the combination of GNAS and KRAS testing was highly specific and sensitive for IPMNs; however, should be interpreted as part of a multidisciplinary approach. Further, the lack of sensitivity for MCNs highlights the need for additional markers to improve the detection of pancreatic mucinous neoplasms. Results: Twenty eight cases were identifi ed (M:F=16/10; age, 27-85 yrs). Only 2 presented with jaundice. Tumors measured 1.5-27 cm (median, 6.9); were ill-defi ned, fl eshy, and multilobulated. All 28 MANECs had evidence of both acinar (trypsin/ chymotrypsin) and NE (chromo/synapto) differentiation in at least 30% of the neoplastic cells. Two also had ductal differentiation (intracellular mucin/IHC labeling for glycoproteins). In 26 of the 28 MANECs, the ACC and NEC components merged intimately and individual neoplastic cells revealed dual differentiation. In fact, 15 cases were originally diagnosed as PDNEC and reclassifi ed as MANEC only after IHC staining was performed. By IHC, 100% of the MANECs expressed chymotrypsin, 95% trypsin, 94% synapto, 80% chromo, and the NEC components had Ki67 indexes of 30%->80%.
None of the 6 cases tested had KRAS mutations. 74% of the patients had nodal and/ or distant metastases at presentation and additional 10% developed distant metastases subsequently. At last follow-up; 11 patients DOD; 13 were AWD. The median survival for all patients was 44 mos (range,1-129) with 1-and 3-yr survival rates of 79% and 56%, respectively (vs 11 mos; and 44% and 21% for PDNECs; p=0.0035). Background: Diagnosis of pancreatic endocrine neoplasm (PEN) on fi ne needle aspiration (FNA) cytology is routine although the assessment of the Ki-67 proliferation index on these specimens is not. Some data suggests that a raised (>2%) proliferation index assessed using Ki-67 correlates with more aggressive behaviour. The current WHO guidelines recommend a mitotic count in "at least 50HPFs" and Ki-67 index as a percentage of 500-2000 cells but because this is a cumbersome and time consuming process, many pathologists choose to "eyeball" the Ki-67 proliferative index despite it being shown to be much less accurate than automated counting. The current study was performed to; 1) assess the feasibility of Ki-67 scoring on cell block sections and 2) compare those results with those obtained from the corresponding histology sections. Design: Twenty patients with a diagnosis of PEN and both an adequate EUS FNA cell block and resection histopathology were selected. Both specimens were assessed for the Ki-67 proliferation index using; 1) "eyeball" examination, 2) manual counting of up to 2000 cells and 3) digital image analysis. The scores were graded using the published cutoffs: G1 2%, G2 3-20%, G3 >20%. For comparison between cytology and histopathology, a consensus grade representing a majority of the three modalities in both types of sample was used.
Conclusions
Results: There was agreement in grading between "eyeball" estimation, manual count and software count in 16 of 20 cell blocks and 19 of 20 histology sections. Comparison of grading between cell blocks and histology showed agreement in 15 of 20 cases and discrepant results in 5 cases, where the histology grading was one level higher than the cell block grading (four were G2 vs G1 and one was G3 vs G2). There were a number of quality control issues affecting the Ki-67 proliferation index assessment, particularly in the cell blocks. Conclusions: Scoring of a Ki-67 proliferation index on cell block section is feasible. There does not seem to be signifi cant variation between "eyeball" examination, manual counting and computerized image analysis. There is reasonable correlation between cell block and histopathology grading although there is a tendency for the cell block to under call the grade, possibly explained by the lack of hot spot identifi cation.
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Proposal for a Revised N-Stage for Pancreatic Ductal Adenocarcinoma as N1 (<3) and N2 (3) with Strong Prognostic Correlation H Choi, B Saka, S Balci, O Basturk, S Maithel, D Kooby, J Sarmiento, B El-Rayes, J Knight, M Goodman, L Ducato, A Goldblum, V Adsay . Emory, Atlanta, GA; WSU, Detroit, MI. Background: There are very few reliable prognosticators for pancreatic ductal adenocarcinoma (PDAC). Although variable data exists, lymph node (LN) involvement from PDAC is associated with poor survival. The discrepancy among different studies exists partly because surgical retrieval and pathologic assessmet of LNs has been highly variable and often inadequate, as highlighted in the NCI's SEER database showing the median number of LNs retrieved to be only "7". Current N-staging of AJCC/UICC TNM recognizes only N0 and N1 categories, but the prognostic impact of the number of metastatic LNs is not known. Design: 250 pancreaticoduodenectomies with PDAC that had undergone "orange peeling" approach of LN harvesting were analyzed. All the LNs were re-evaluated by the authors for the presence of carcinoma as well as the number of LNs involved. Applicability and prognostic value of a revised N-stage protocol similar to that used in other organs as N0, N1 (1-2 LNs) and, N2 (3) was analyzed.
Results: The median number of lymph nodes examined was 19 (3-45) . 194 (78%) cases had LN positivity. Median number of positive LNs was 3.4 (0-20) . Median survival of LN negative cases was signifi cantly better than LN positive cases (24 vs 13 mos) (p=0.0079). When LN-positive cases were reclassifi ed according to the proposed sub-staging protocol, 69 cases (28%) were N1, and 125 cases (50%) were N2. The median estimated survival under this new classifi cation was 18, 16 and 12 months, respectively. The 1-, 3-and 5-yr survival rates of N0 cases were 72%, 41%, 32%, N1 was 66%, 30%, 16%, and N2 was 59%, 19%, 10% (p=0.0126)( Figure 1 ). As expected, these differences seemed to be even stronger when only cases with more than 12 LNs were analyzed separately (p=0.0104).
Conclusions:
Sub-staging of nodal status in pancreatic ductal carcinomas as N1 and N2 based on the number of metastatic LN as <3 vs≥3 has signifi cant prognostic value. A revised N-staging protocol should be incorporated into the TNM-staging of pancreas cancers in the next edition of AJCC/UICC. 
Background:
The NFAT family as a regulator of T cell activation is composed of four calcium-responsive isoforms. Recent studies suggest that NFAT1 and NFAT2 are key regulators of neoplastic transformation and cancer progression but the role of NFAT3 is still unknown. This project aims to study expression of NFAT3 in human pancreatic adenocarcinoma and decipher the impact of NFAT3 on pancreatic cancer cell proliferation. Design: Immunostaining for NFAT3 was performed on18 paraffi n-embedded human pancreatic adenocarcinoma, their adjacent PanIN lesions and paired non-neoplastic pancreas. The proper positive and negative controls were also established. Based on the staining intensity, the staining of the pancreatic tissues was classifi ed as no staining (0), low intensity staining (+) or high intensity staining (++). We use two human pancreatic cancer cell lines (AsPC-1 and PANC-1) to decipher the effect of NFAT3 on cancer cell proliferation in vitro. Small interfering RNA (siRNA) and cyclosporine A were used to block NFAT3 expression and activity. Flow cytometry was used for cell cycle analysis. Expression of cell cycle regulating proteins was evaluated by western blot. Results: Distinct aberrant expression of NFAT3 was identifi ed in infi ltrating pancreatic ductal adenocarcinoma. 78% (14/18) pancreatic adenocarcinoma show intense staining for NFAT3. The positive staining was identifi ed in cytoplasm and nuclei of tumor cells. NFAT3 was negative in normal pancreas, chronic pancreatitis and all PanIN lesions. Inhibition of NFAT3 by siRNA or cyclosporine A markedly blocks pancreatic cancer cell proliferation and arrests tumor cells at G0/G1 phase in vitro. Western blot analysis reveals that inhibition of NFAT3 signifi cantly decreases expression of two cell cycle regulating proteins, Cyclin D1 and Cyclin E.
Conclusions:
This study has clearly demonstrated an aberrant expression of NFAT3 in human infi ltrating pancreatic adenocarcinoma. NFAT3 might be a useful malignant biomarker to differentiate pancreatic adenocarcinoma from pre-malignant and nonneoplastic lesions. NFAT3 regulates pancreatic cancer cell proliferation through down-regulating Cyclin D1 and Cyclin E expression, which further warrants exploring the role of NFAT in pancreatic carcinogenesis and as a potential target for treatment of pancreatic cancer. metastasis/invasion into adjacent organs), and rarely, die from their disease. While the clinicopathologic features associated with aggressive SPNs have been reported, important prognostic factors of survival remain unclear. Design: We systematically reviewed 64 cases of SPN resected at our institution for tumor size, extent of invasion, margin status, presence of lymphovascular invasion, muscular vessel invasion, perineural invasion, lymph node and/or distant metastases. Clinicopathologic characteristics were correlated with the presence of metastasis/ recurrence and disease-specifi c survival. Results: Five (8%) patients presented with stage IV disease. Among them, 2 died of disease (one at 2.5 months due to extensive peritoneal tumor involvement and one at 19 months due to multiple liver metastasis and peritoneal seeding), 2 were alive with disease at 69 and 86 months and one had no evidence of disease at 44 months after resection of recurrent disease. During follow-up, 5 (13%) of 39 patients with stage I-II disease had recurrences. Patients with metastatic/recurrent SPNs had signifi cantly larger tumor size (p<0.001) and more frequent tumor invasion of muscular vessels (p=0.02). Tumor invasion into muscular vessels (p=0.001), Tumor (T) stage by European Neuroendocrine Tumors Society (ENETS) classifi cation (p<0.001), ENETS stage grouping (p<0.001) and stage grouping by the American Joint Committee on Cancer (AJCC stage, p<0.001) are important predictors of disease-specifi c survival in patients with SPN.
Our study highlights the importance of including the presence of vascular invasion and staging information in surgical pathology reports, for risk assessment and guide clinical management in patients with SPNs. , each one is associated with unique clinicopathological features and biology. Of those, IPMN-I makes up for the majority of main duct-type IPMN often exhibits high-grade dysplasia (HGD) with or without invasive carcinoma. KRAS and GNAS mutations are found in 60-70% of IPMNs. Interestingly GNAS mutations have been reported in villous adenomas of the colorectum and low-grade appendiceal mucinous neoplasms that exhibit similar morphology to IPMN-I. Thus, we hypothesized that GNAS mutations are associated with an intestinal lineage in IPMN. Design: We analyzed GNAS and KRAS mutations in 60 IPMN foci with various epithelial types and dysplastic grades from 44 patients using a PCR-based multiplex assay. Results: GNAS +/-KRAS mutations were identifi ed in >90% of IPMN-I, irrespective of grade. In IPMN-G, 65% of foci harbored GNAS +/-KRAS mutations and 24% exhibited KRAS mutations only. However, 90% of IPMN-G foci found in association with IPMN-I (n=10) showed GNAS +/-KRAS mutations. Although limited in number, IPMN-PB with or without microinvasion often exhibited KRAS mutations only. Table 1 KRAS mut/ GNAS wt
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GNAS
LGD: low-grade dysplasia **microinvasive carcinoma arising in IPMN-PB or IPMN-I Among the 9 cases with multiple foci examined, 5 cases with IPMN-I and IPMN-G foci and 1 case with different grades of IPMN-I]harbored exact same mutations in all foci within one case. Conversely, 3 cases contained IPMN-PB or IPMN-O showed different KRAS mutations in high-grade foci and IPMN-G, suggesting multi-lineage lesions.
Conclusions:
The vast majority of IPMN-I and IPMN-G foci in the background of IPMN-I harbor GNAS mutations, suggesting GNAS mutations are involved in intestinal differentiation in IPMN. Our data also suggest some IPMN lesions, especially with pancreatobiliary-and/or oncocytic-type epithelium, molecularly appear to be multilineage. A larger cohort study to confi rm these fi ndings is underway.
AST/GOT1 Expression Status in Primary Resection Specimen Is a Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma
FM Feld, PD Nagel, C Welke, P Moller, JK Lennerz. University Ulm, Ulm, Baden Wuerttemberg, Germany. Background: Oncogenic KRAS mutations are a hallmark of pancreatic ductal adenocarcinoma. Recently, a metabolic function of the KRAS mutation has been established (nature 2013; Apr 4; 496:101-5). Specifi cally, KRAS acts as a modulator of the cancer cell's redox maintenance system, which goes along with an increase in the glutamic-oxalacetic transaminase 1 (GOT1) expression. The clinical relevance of this metabolic KRAS-GOT link has not yet been assessed in primary human patient samples. Thus, here we studied whether the GOT1 expression status (a) correlates with the KRAS mutation status, (b) can be identifi ed via specifi c clinicopathological phenotypes and (c) has prognostic relevance. Design: Two independent cohorts were analyzed: the fi rst, 'international cancer genome consortium; (ICGC, 57 patients with whole-exome sequencing data, genome wide expression profi le, clinicopathological (CPC) data and follow up) and second, 'Ulm' (124 patients with basic molecular genetic workup, tissue-microarray, CPC data and follow up). GOT1 expression was assessed via RNA levels (ICGC) and by immunohistochemistry (Ulm). Contingency and outcome analyses employed t-tests, Fisher's exact test, chi-square and log-rank statistics. Multivariate comparisons were modeled after univariate results; statistical signifi cance was defi ned as P<0.05. Results: The GOT1 expression status was not predictive of the KRAS mutation status (P=0.2 (ICGC), P=0.7 (Ulm); both Chi-square). The lack of association indicates that GOT1 assessment cannot serve as a surrogate marker for KRAS mutation testing and that additional modulatory factors are at play in the KRAS-GOT axis in primary human tumor samples. Phenotype comparison revealed that GOT1 high/positive subgroups do not differ by age, sex, T, N, M, overall stage grouping or tumor grading (P=0.39-1.00). Thus, the GOT1 subgroups cannot be distinguished based on clinicopathological phenotype. Outcome analysis revealed that patients with GOT1 high-expressing tumors had signifi cantly longer overall survival times when compared to the low-expressing tumors (P=0.0483 ICGC), which was verifi ed by immunohistochemistry in the Ulm cohort (P=0.0488). Uni-and multivariate analyses and cohort comparisons showed that GOT1 expression status is an independent prognostic factor in up to 68% of tumors.
Conclusions:
The biology of the KRAS-GOT mechanism is seemingly more complex than in cellular models and will have to be delineated; however, our results specify that the GOT1 status is a valuable prognostic biomarker in pancreatic ductal adenocarcinoma.
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The Pathology of Type 2 Autoimmune Pancreatitis: A Retrospective Analysis of Cases Resected over Last 2 Decades RK Gupta, V Deshpande. University of Tennessee HSC -College of Medicine, Memphis, TN; Massachusetts General Hospital and Harvard Medical School, Boston, MA. Background: The 2 variants of autoimmune pancreatitis (AIP), type 1 AIP and type 2 AIP are associated with distinct clinical and histopathologic features. Although the features of type 2 AIP have been delineated in previous studies, there has been no systematic evaluation of the pathology of type 2 AIP in North America. Design: Pancreatic resections between 1993 and 2012 diagnosed as chronic pancreatitis at Massachusetts General Hospital were reviewed. The available HE slides were graded for the intensity of chronic periductal infi ltrate from 0 to 3. Active infl ammation in the form of neutrophils were also graded from mild, moderate (abscesses) and severe (ulceration). A diagnosis of type 2 autoimmune pancreatitis required the presence of either grade 2 periductal chronic infl ammation or grade 1 associated with neutrophils. Relevant demographic and clinical data was collected. Immunohistochemistry for IgG4 was performed. Results: We identifi ed 38 cases of type 2 AIP, constituting 17.3% of cases analyzed. The cohort consisted of 34 Whipple resections and 4 distal pancreatectomy specimens. The mean age of the patients was 51 years. A slight male predominance was noted (M:F = 21:17). The most common presenting symptom was abdominal pain (33 cases) followed by weight loss (15 cases) and jaundice (6 cases). History of alcohol abuse and smoking were identifi ed in 5 cases each. A diagnosis of pancreatitis (14 cases) or pancreatic mass (12 cases) was the usual indication for pancreatic resections. The periductal lymphoplasmacytic infi ltrate ranged between grade 1 (9 cases), grade 2 (15 cases) and grade 3 (14 cases).The intensity of neutrophilic infi ltrate also varied considerably. Intraductal abscesses with tissue necrosis were seen in 4 cases and acinar infl ammation in 15 cases. Dense interlobular fi brosis was identifi ed in 34 cases. Other fi ndings included non-obliterative phlebitis (9 cases), prominent eosinophilia (10 cases), lymphoid aggregates (7 cases) and periductal granulomas (2 cases). Six patients had a history of infl ammatory bowel disease. 5 out of 8 cases showed less than 10 IgG4 positive cells per HPF.
Conclusions:
The presence of periductal infiltrate defines a unique variant of pancreatitis. In this surgical series type 2 autoimmune pancreatitis is a common infl ammatory disease of the pancreas. Some cases of type 2 AIP however shows overlapping clinical and histological features with ethanol-related chronic pancreatitis.
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Prognostic Role of Neuroendocrine Differentiation in Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Study RK Gupta, DD Santos, C Ferrone, V Deshpande. University of Tennessee HSC College of Medicine, Memphis, TN; Massachusetts General Hospital, Boston, MA. Background: Foci of neuroendocrine differentiation are identifi ed in virtually all solid epithelial tumors of the gastrointestinal tract, including pancreatic adenocarcinoma (PDAC). Previous studies have suggested that the presence of neuroendocrine cell differentiation in pancreatic adenocarcinoma predicts improved survival. We investigate the prognostic relevance of neuroendocrine cell differentiation in a large cohort of pancreatic adenocarcinomas resected with the intent to cure. Design: We identifi ed a cohort of 391 PDACs with available follow-up information. Tissue microarrays (TMAs) composed of 3 mm core of tissue were constructed from these specimens. At least 2 cores were included from each patient. Clinical, demographic and survival data were recorded. An immunohistochemical stain for chromogranin was performed and the reactivity of the tumor cells was scored as positive or negative. Reactivity within tumor cells was distinguished from that in neuroendocrine cells colonizing malignant glands which was also scored similarly. This latter phenomenon was manifest by the presence of neuroendocrine cells at the abluminal surface of the ducts. Results: Chromogranin reactivity was identifi ed in 32 of 391 cases (8.1%). The reactivity in tumor cells varied from rare weakly positive staining to diffuse and strong staining. The immunoreactivity within the neoplastic cells was signifi cantly less than in normal islets and endocrine cells involved in the colonization. Although the PDACs with positive staining showed a lower median survival when compared to those without reactivity for chromogranin (estimated median survival 42 months versus 49 months), this difference was not statistically signifi cant (log rank test 0.8). Colonization was identifi ed in 109 cases (28%). There was no difference in the median survival between cases with colonization (48 months) and those without colonization (49 months) (log rank test 0.9).
Conclusions:
The presence of neuroendocrine reactivity within pancreatic ductal adenocarcinoma does not infl uence overall survival. Colonization by neuroendocrine cells is common in PDAC, and represents a potential pitfall, particularly on biopsy samples.
GNAS Mutations Are Frequent in Pancreatic Adenocarcinomas with Mucinous Phenotype
Aichi Cancer Center Hospital, Nagoya, Japan. Background: GNAS encodes the alpha-stimulatory subunit of heterotrimeric G-proteins which is crucial for the cyclic AMP-mediated signal transduction. Recently, intraductal papillary mucinous neoplasm (IPMN) has been reported to show frequent GNAS mutations, in contrast to pancreatic ductal adenocarcinoma (PDA). The aim of this study is to examine clinicopathological characteristics of GNAS mutation in various pancreatic carcinomas. Design: We examined codon 201 of GNAS and codon 12, 13, and 61 of KRAS using a series of 290 surgically resected pancreatic tumors, including 88 PDAs, 3 colloid carcinomas, 29 IPMN-associated adenocarcinomas, 61 IPMNs, 10 mucinous cystic neoplasms, 52 neuroendocrine neoplasms, 16 acinar cell neoplasms, 10 serous neoplasms, and 14 solid-pseudopapillary neoplasms, in addition to microdissected 77 PanIN lesions. In 29 IPMN-associated adenocarcinomas, the components of IPMN and adenocarcinoma were microdissected and examined separately. Results: GNAS mutations were frequently detected in colloid carcinomas (67%, 2/3), IPMNs (64%, 39/61), and IPMN-associated adenocarcinomas (38%, 11/29). In contrast, other histological subtypes including PDAs (1%, 1/88) and a precursor lesion of PDA (PanIN, 3%, 2/77) rarely harbored GNAS mutation. Frequent KRAS mutations were detected in PDAs (92%, 81/88), IPMN-associated adenocarcinomas (76%, 22/29), IPMNs (59%, 36/61), and mucinous cystic neoplasms (40%. 4/10). When IPMNassociated adenocarcinomas were subcategorized into mucinous and tubular subtypes, the mucinous subtype showed higher frequency of GNAS mutation (83%, 5/6) than those of the latter subtype (26%, 6/23) (p=0.02). Furthermore, mucinous subtypes shared clinicopathological characteristics with IPMN. The difference between the two subtypes in IPMN-associated adenocarcinoma were highlighted by concordance of the genotypes between the components of IPMN and adenocarcinoma; all mucinous-subtype tumors showed identical genotypes between the two components in individual tumors, whereas 8 of 23 tubular subtypes were different in their genotypes. Conclusions: Our study suggested that GNAS mutated tumors, including IPMN, IPMNassociated adenocarcinoma, particularly mucinous subtype, and colloid carcinoma, constituted a spectrum of pancreatic tumors. Although the clinicopathological association among these tumors have been reported, GNAS mutation further sheds light on the spectrum.
ZIC2 Is an Indispensable Transcriptional Factor for the Cell Growth of Pancreatic Ductal Adenocarcinoma
Aichi Medical University School of Medicine, Nagakute, Aichi, Japan. Background: ZIC2 is one of fi ve members of ZIC family gene that contain a C2H2-type of zinc fi ngers and function as a transcriptional regulator. As a part of Hedgehog signal molecules, ZIC2 is indispensable for the development of central nervous system and its mutation causes holoprosencephaly, the most common structural anomaly of the human brain. Recently, we uncovered that ZIC2 is a unique member which is over-expressed in all (11/11) of the pancreatic ductal adenocarcinoma (PDAC) cell lines we tested. We also found that ZIC2 knockdown by the siRNAs lead to the apoptotic cell death of PDAC cells. In contrast, Tet-induced ZIC2 expression accelerated PDAC cell proliferation. In this session, we would like to highlight the importance of ZIC2 over-expression in PDAC cells from the point of ZIC2 transcriptional target genes. Design: We employed siRNA-mediated ZIC2-knockdown PANC-1 cells and Tetinduced ZIC2-over-expressed PANC-1 cells for cDNA expression microarray analysis using Agilent 4x44K cDNA microarray. Concerning the identifi ed ZIC2 transcriptional targets, we performed over-expression and knockdown experiments using PDAC cells to uncover how the ZIC2 transcriptional targets regulate PDAC cell apoptosis and growth. Finally, we performed immunohistochemical analysis to assess the relationship between the ZIC2 and its target gene expressions or cell proliferation marker Ki-67 labeling index in 20 cases of resected PDAC tissue. Results: Among the 43 identifi ed ZIC2 target genes, we focused on ANXA8L2 and FGFR3 in this session. Forced expression of ANXA8L2 partly reduced the apoptotic cell death of the ZIC2-knockdown PDAC cells. On the other hand, combined transfection of the ZIC2 expression vector and FGFR3 specifi c siRNAs revealed that ZIC2 activated RAS-MAPK pathway in a FGFR3 dependent manner. The ZIC2, ANXA8L2 and FGFR3 expressions were immunohistochemically under-detectable levels in the normal pancreatic duct. Their expression was weakly identifi ed in low-grade PanIN and prominent in high-grade PanIN and PDAC cells, respectively. There were positive correlation between ZIC2 and ANXA8L2 (=0.774, p<0.0001) or FGFR3 (=0.828, p<0.0001) expression. We also uncovered the positive correlation between the ZIC2 expression and Ki-67 labeling index (=0.773, p<0.0001). Conclusions: Our experimental results indicate that ZIC2-ANXA8L2 and ZIC2-FGFR3-MAPK axis are important signaling pathways for the regulation of apoptosis and proliferation in the PDAC development. Background: There is virtually no information on the frequency and clinicopathologic characteristics of ampullary mucinous carcinomas(MCs). Design: 359 well-characterized ampullary carcinomas (AC) were reviewed. Nonampullary duodenal, pancreatic  distal CBD carcinomas were excluded by purist's approach. Results: Mucinous differentiation (stromal mucin deposition) was identifi ed in 59 ACs (16%). 26 (7%) of these had mucin <50% of the tumor and were excluded as carcinoma with focal mucin production, and the remaining 33 (9%) was further analyzed as MC and contrasted with other ACs: M/F=24/8 (vs 182/138); mean age=63 (vs 65). 27% of MCs were from the duodenal surface of the ampulla (vs 5%). Invasive carcinoma size was larger for MCs (mean, 25.3 vs 18.1 mm; p=0.001). 30% contained acellular mucin lakes, but only 6% were pure colloid type. Signet ring cells in mucin were identifi ed in 36%. Non-mucinous component (cellular infi ltrates into the stroma) was present in 28/33 and often contained multiple patterns in a mixture: Tubular-intestinal 13, tubular-pancreatobiliary 12, micropapillary 7, poorly diff 7, signet ring cell 6, and squamous 1. Almost half (46%) had signifi cant preinvasive (adenomatous) component, mostly intestinal (65%) or mixed (22%); rarely gastro-pancreatobiliary lineage (11%) . None of the 15 MCs analyzed revealed loss of MMR proteins by IHC (vs loss in 12/68 other ACs and in 6/11 carcinomas with focal mucin). T stage distribution was similar to other ACs. The frequency of LN metastasis was higher but this was not statistically signifi cant (63% vs 44%; p=0.06). Overall 3- 5-yr survival was not different from other ACs (59% and 49% vs 61% and 47%; p=0.92).
Of note, including carcinomas with focal mucin did not bring any survival difference. Conclusions: MC (stromal mucin >50% of the tumor) constitutes 9% of ACs. Most are mixed-mucinous type. Almost half are associated with adenomatous component, mostly intestinal type. Unlike their lower-GI counterparts, these tumors do not show association with MSI, although those with lesser mucin production might. Despite their large size and common (63%) LN metastasis, the prognosis of these tumors does not seem to be worse than that of other ACs. Insights into the Pathogenesis of Such Rare Cancers S La Rosa, B Bernasconi, M Frattini, N Sahnane, F Molinari, MG Tibiletti, D Furlan, L Zang, A Vanoli, S Casnedi, V Adsay, K Notohara, L Albarello, S Asioli, F Sessa, C Capella We investigate p53 alterations (mutation, methylation, and loss) in 44 ACCs using direct sequencing of exons 4-8, MS-MLPA, and FISH. In addition, we evaluated nuclear p53-IR by immunohistochemistry. Results: p53 mutations were found in 8/44 (18%) cases. They correlated with higher tumor stage (5 cases were at stage IV) and, in one case, it was observed in the metastasis of a primary p53 wild type ACC. p53 gene loss, including 17p13 deletion and monosomy of chromosome 17, was found in 50% of ACCs and it was associated with mutation in 4 cases. p53 methylation was observed in only one case. p53 alterations correlated with p53-IR. The simultaneous presence of both p53 mutation and loss correlated with worse prognosis (p:0.001). Conclusions: p53 alterations including mutations and cytogenetic loss are frequent in ACCs and correlated with higher tumor stage and a more aggressive behavior suggesting that p53 is not early involved in ACC tumorigenesis, but later in cancer progression. Use of microRNA in diagnostic applications has been limited by inability to determine expression patterns in situ on a cellular level, as profi ling-based strategies using tissue homogenates may not adequately resolve expression differences in tumor microenvironment. Design: 13 cases of CCs (12 intrahepatic and 1 extrahepatic) and 18 cases of PDACs were used in the study. Cases were subjected to in situ hybridization (ISH) using FAMlabeled miRNA probes (BioGenex) for miR-21, miR-10b, miR-196a and miR-216a followed by super sensitive ISH Detection Kit (BioGenex, DF400-YAX). Nuclear staining was evaluated semi-quantitatively by intensity (low, no or weak stain; high, moderate to intense stain). Statistical analysis was performed by using Fisher's exact two-tailed test. Results: High level expression of both nuclear miR-196a and miR-216a expression was seen in 85% (11/13) of CC. PDAC cases showed high level expression of nuclear miR196a and miR-216a expression in 22% (4/18) and 28% (5/18) cases, respectively, which was signifi cantly different from CC (p<0.01). No signifi cant difference in the expression of miR-21 and miR-10b was identifi ed between the CCs and PDACs (both P>0.05). Conclusions: miR-196a and miR-216a expression were upregulated in CC compared to PDAC. This study demonstrates feasibility of an "in situ" evaluation in FFPE where morphologic control of cells of interest and differentiating cancer and benign cell expression is retained. Ongoing studies in a larger cohort are underway to fully assess the potential of these markers in differentiating CC from PDAC. . Ninety percent of patients within the cohort did not receive initial adjuvant chemotherapy, either due to patient preference, poor performance status, or low-risk clinical characteristics, yielding a 3-year progression free survival (PFS) of AC-IT 72% vs AC-PB 55% (p=0.27) and a 3-year overall survival (OS) of AC-IT 53% vs AC-PB 46% (p=0.57) in the untreated cohort. Three patients with AC-PB were initially treated with 5-FU (n=2) and gemcitabine (n=1) regimes; an additional AC-PB patient, without initial chemotherapy, had a recurrence 17 months after resection and was subsequently treated with gemcitabine. One patient initially treated with 5-FU recurred 9 months after start of therapy, while the two patients on gemcitabine were alive at 3 years. OS for the entire cohort at 3 years demonstrated no difference between the two histological subtypes with 63% of patients alive. Conclusions: Although OS and PFS were not statistically signifi cant in our cohort, patients with PB subtype tended to show a lower probability of survival and higher chance of recurrence at 3 years. Interestingly, two AC-PB patients treated with gemcitabine were alive three years after resection. Despite the small sample size and short follow-up this study highlights the heterogenous nature of AC and makes the case that histological subtyping may be of value to stratify patients for chemotherapeutic treatment.
1854 CD5 Is Highly Sensitive and Specific for Pancreaticobiliary Adenocarcinoma GH Lewis, RB West, RK Pai, TA Longacre. Stanford University, Stanford, CA; University of Pittsburgh, Pittsburgh, PA. Background: Determining the site of origin in cases of metastatic adenocarcinoma of unknown primary, where the differential diagnosis includes pancreatobiliary and upper gastrointestinal primaries presents a challenge for pathologists. Sensitive and specifi c markers for these sites are lacking. The expression of CD5 and CD7 in epithelial neoplasms has previously been reported. We studied the expression of CD5 and CD7 in a series of tissue microarrays (TM) containing pancreatobiliary (PBA), gastric (GA), breast (BrA), and lung (LA) adenocarcinomas and report the sensitivity (SN), specifi city (SP), positive (PPV) and negative predictive values (NPV) for predicting site of origin. Design: TM containing 62 PBA, 82 GA, 19 BrA, and 8 LA were stained for CD5 and CD7. Any expression was scored positive. Results: CD5 expression was seen in 87% of PBA, 44% of GA, 16% of BrC, and 0% of LA. CD7 was negative in all cases except 2% of GA. Compared only to BrC and LA, the SN, SP, PPV, and NPV for PBA are 87%, 89%, 95%, and 75%, respectively; while for GA they are 44%, 89%, 92%, and 34%, respectively. Compared to BrC, LA, and GA, the SN, SP, PPV, and NPV for PBA is 87%, 64%, 58%, and 90%. The SN, SP, PPV, and NPV of CD7 for GA is 2%, 100%, 100%, and 53%. Conclusions: CD5 is highly sensitive and specifi c for PBA especially if GA is not in the differential diagnosis. While CD7 is highly specifi c for GA, it is not as diagnostically useful due to low sensitivity. CD5 is a potentially useful marker for the diagnosis of PBA and to a lesser extent, GA in metastatic adenocarcinoma of unknown primary.
Excision Cross-Complementing Gene1 and X-Ray Repair CrossComplementing 1 Gene as Prognostic Markers in Biliary Cancer
M Mian, MG McNamara, DW Hedley, JJ Knox, S Serra. University Health Network, Toronto, Canada. Background: Excision cross-complementing gene1 (ERCC1) and X-ray repair crosscomplementing 1 gene (XRCC1) are important for DNA repair. Previous studies have thus examined the tissue expression of these genes in a variety of cancers but the results affecting treatment outcomes have been variable. One study in biliary cancer examined ERCC1 expression but did not relate this to treatment. The aim of the current study was to evaluate the expression of both ERCC1 and XRCC1 protein in biliary tract malignancies and access the prognostic value of these markers on outcome. Design: All cases of biliary tract (gallbladder, extrahepatic, Klatskin and intrahepatic cholangiocarcinomas) cancer with available tumour from 2000 to 2013 diagnosed at University Health Network, Toronto, Canada were initially chosen and those with adequate follow-up were selected for the study. Relevant clinicopathological information, chemotherapy and survival data were obtained. A TMA was constructed and stained for ERCC1 and XRCC1. Each case was scored as high or low based on a product of intensity and percentage of tumour cells stained. Results: Of 71 patients, 40 were males. The mean patient age was 65.5 years with mean overall survival of 26 months (range 0.5 -97.9 months). Twenty eight (39.4%) patients received adjuvant chemotherapy. Immunohistochemistry showed 40 (56.3%) high XCCR1 (-H) and 18 (25.4%) high ERCC1 (-H) tumors. XRCC1-H expression correlated with longer mean survival in all patients (31.1 vs 19.33 months; p<0.01), and by treatment in the chemo-treated (35.4 vs 20.3 months; p=0.008) and non-treated groups of patients (28.8 vs 18.5 months; p=0.019). ERCC1-H correlated with longer mean survival (33. 4 vs 24. 9 months; p=0.013) in the group of chemo treated patients, but did not correlate with outcome in the non-treated group. Conclusions: High expression of XRCC1 and ERCC1 are associated with longer survival in biliary cancer, and this may be improved with adjuvant chemotherapy. This warrants further study in larger series. Background: Intraductal papillary mucinous neoplasms (IPMNs), mucin-producing tumors arising within the pancreatic ductal system, are a recognized precursor lesion for pancreatic colloid carcinoma. Given the increased intraluminal pressure within the ductal system spillage of mucin into the extraductal stroma may occur. Although a diagnosis of colloid carcinoma arising within an IPMN is usually uncomplicated in the setting of neoplastic cells 'fl oating' within the mucin pools, the prognostic signifi cance of acellular stromal mucin spillage has yet to be determined. Design: Archival cases of IPMN (n=27), resected at Vancouver General Hospital between 2006-2012, with associated clinical outcome data were reviewed and stratifi ed into two groups: with (mIPMN; n=10) and without (IPMN; n=17) extravasation of mucin into the stroma. Demographic information, histologic attributes considered to be associated with a higher potential of malignant transformation of IPMNs and follow-up data (range 1-6 yr) were compared between the two groups. Results: IPMNs with stromal mucin extravasation (mIPMN) trended to occur at a later age (mean [yr] 68.1 vs 65.6), be larger in size (mean [cm] 3.04 vs 2.31) and were more commonly situated in the main pancreatic duct. No signifi cant differences were identifi ed in regards to histological grade and subtype (see fi gure 1). Overall survival (OS) at 1 and 2 year time points after initial diagnosis did not show any recurrences or death within either group.
Duodenal Invasion Is Under-Staged in Distal Bile
Conclusions:
While mIPMNs possess histologic characteristics associated with a higher risk phenotype, such as main duct subtype and larger size, no difference in survival or recurrence rate was identifi ed. Although this study is limited by the overall short term follow-up data and the cohort size, acellular mucin pools associated with IPMNs do not appear to carry a worse prognosis than those without.
Low Nuclear Accumbens-1 Expression Is Related to Poor Prognosis in Pancreatic Ductal Adenocarcinoma; an Effect Opposite from Gynecological Carcinomas
T Nishi, R Maruyama, A Araki, N Ishikawa, T Urano, N Nakayama, K Nakayama, M Yoshida, Y Tajima. Shimane University School of Medicine, Izumo, Japan; Matsue Municipal Hospital, Matsue, Japan. Background: Nucleus accumbens-associated protein 1 (NAC1) is overexpressed in various carcinomas including ovarian, cervical, breast, and pancreatic carcinomas. High expression of NAC1 is considered to have adverse effects on prognosis through negative regulation of growth arrest and DNA-damage-inducible 45-interacting protein 1 (GADD45GIP1) in ovarian and cervical carcinomas. Recently we found that low expression of NAC1 was related to poor prognosis in pancreatic ductal adenocarcinoma (PDA), totally opposite effect from the result of gynecological cancers. We report the relationship between immunohistochemical expression of NAC1 in invasive PDA and clinicopathological parameters, and GADD45GIP1 expression and invasion assay after siRNA knockdown of NAC1 using pancreatic cancer cell lines.
Design: From 2000 to 2010, we retrieved 67 appropriate cases with typical invasive PDA. The median follow-up duration after surgical resection was 12.8 months (range: 0.3-72 months).The expression of NAC1 was measured using immunohistochemistry (IHC), and the IHC results were objectively analyzed by computer-assisted image analysis on the IHC-stained slides converted to whole slide images (as known as virtual slides) in order to investigate its correlation with various clinicopathological parameters and prognosis. The expression of GADD45GIP1 after knockdown of NAC1 of PDA cell lines was analyzed by Western blot, and invasion assay was also performed using Matrigel. Results: Patients with low NAC1 PDA had worse overall survival (P=0.0010) and a shorter disease-free survival (P=0.0036) than patients with high NAC1 PDA. This was a clinical effect totally opposite from that reported in ovarian and cervical carcinomas. Low NAC1 group was correlated with more frequent venous invasion (P=0.047) and lymph node metastasis (P=0.0017) and higher UICC clinical stages (P=0.02) than high NAC1 group. Furthermore, knockdown of NAC1 in pancreatic carcinoma cell lines did not increase expression of the GADD45GIP1 protein. In addition to it, invasion assay showed signifi cantly increased invasive ability of the cancer cells after knockdown of NAC1. Conclusions: These results indicate that the gene(s) regulated by NAC1 vary depending on the types of carcinoma or originating tissue, and that low expression of NAC1 predicts poor prognosis for patients with PDA. This fi nding may help physicians choose appropriate treatment options and give patients proper information about their prognosis. th most common cause of cancer related death in North America. Tumor budding is a well-established adverse prognostic factor in colorectal cancer, and in this setting budding is associated with a lesser degree of peri-tumoral infl ammation. However, the signifi cance of tumor budding in PDAC is uncertain; one previous study has shown budding to be an independent prognostic factor. We aimed to assess the prognostic signifi cance of tumor budding in PDAC, and to determine its relationship with peritumoral infl ammation. Design: Archival cases of PDAC (n = 192) were assessed for tumor budding using HE sections only; tumor buds were defi ned as single tumor cells or clusters consisting of <5 cells. The slide with the highest amount of budding was selected and assessed for the presence of high-grade budding (10 buds/10 HPF) or low-grade budding (<10 buds/10HPF). The numbers of tumor infi ltrating lymphocytes (TILs) were counted, and peri-tumoral lymphocytes and neutrophils were scored semi-quantitatively. These features were then correlated with baseline clinicopathologic features and outcome. Results: High-grade budding was present in 138/192 cases (72%), low-grade budding was present in 32/192 cases (17%), and there was no budding in 22/192 cases (11%). The presence of budding was associated with inferior overall survival and there was no signifi cant difference in overall survival between those with high-and low-grade budding. On multivariable analysis, tumor budding was prognostic independent of T-stage, grade, nodal status, lymphovascular and perineural invasion. Other independently prognostic variables included grade, and nodal status (Table 1) . There was no signifi cant relationship between tumor budding and the degree of peri-tumoral infl ammation or number of TILs. Conclusions: Tumor budding is independent adverse prognostic factor in PDAC. The assessment of budding can be performed on HE slides and may therefore be readily implemented into routine practice. Background: A previous analysis of carcinoma "in-situ" (CIS) of gallbladder (GB) reported to the NCI's Surveillance Epidemiology End Results (SEER) program demonstrated 5-and 10-yr survival estimates of 100% and 70%, respectively. In our experience from high-incidence regions, early-gallbladder carcinoma, which also includes minimally invasive mucosa-confi ned carcinoma has a very good prognosis with 10-yr survival of 90%, if the GBs are sampled entirely and the possibility of a more advanced carcinoma has been carefully ruled out. Design: 685 cases recorded as CIS of GB in the SEER database, 1973-2010, with survival information, were analyzed. In addition to observed survival, relative survival, which is more relevant to older population, was also calculated based on the expected survival in the general population with the same demographics. Cases with additional designation of "adenoma", "papillary" or "villous" were regarded as possibly representing tumoral forms of CIS (adenoma-associated or intracholecystic papillary neoplasm-associated) and grouped as "tumoral".
Tumor Budding Is an Independent Adverse Prognostic Factor in
"Carcinoma In
Results: 80% of the patients were white, 69% were female, and almost half (49%) were≥ 70 yrs old. Observed survival was 91% at 1-yr, 80% at 3-yr, 72% at 5-yr, 53% at 10-yr. The corresponding 1-, 3-, 5-, 10-yr estimates for relative survival were 94%, 89%, 87% and 79%, respectively. Survivals were generally slightly higher for "tumoral" cases compared to "fl at" cases. Conclusions: Cases recorded as "in-situ" carcinoma of GB in the SEER database are mostly elderly females. The 10-yr survival of 79% is worse than what would be expected from the early-gallbladder carcinoma data from high-risk regions (10-yr survival, 90%). This difference is likely attributable to under-sampling or underdiagnosis (GBs with CIS are submitted entirely in high-risk regions but not in the US). In particular, deaths within 1 year likely represent underdiagnosed higher-stage carcinomas. Of the deaths in longer F/U, some likely represent the true CIS cases, and as such may refl ect a fi eld-defect/effect phenomenon in the biliary tract. Tumoral CIS of GB may have slightly better prognosis. It is imperative for pathologists to examine GBs entirely to rule out advanced carcinomas, and for clinicians to place these patients in long-term F/U. Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Even for the patients who undergo pancreatectomy, the clinical courses and prognosis vary with survival ranging from few months to more than 10 years. The aim of this study is to compare the clinicopathologic factors associated with short and long survival after pancreatectomy. Design: Our study population consists of 95 long survivors (survival>5 years after pancreatectomy) and 74 short survivor (survival <1 year after pancreatectomy) who underwent pancreatectomy at our institution. The HE slides from all cases were reviewed. The clinicopathologic data were obtained by reviewing the medical records, including age, gender, family and personal history of cancer, tumor stage, lymph node status, resection margin, lymphovascular and perineural invasion, and neoadjuvant therapy. Fisher's exact tests were used to determine the statistical signifi cance. Results: The long and short survivor groups were not statistically different for age (62.6 ± 9.5 years vs 64.6 ± 9.5 years), gender (45.3% vs 37.8% females), neoadjuvant therapy (67% vs 54% respectively, P=0.08) and types of resection (pancreaticoduodenectomy 99% vs 93% respectively, P=0.09). Long survivors had lower tumor (pT) and American Joint Committee on Cancer (AJCC) stage; lower frequencies of lymph node metastasis, positive resection margin, lymphovascular and perineural invasion; and lower recurrence rate than short survivors (P<0.05). During the follow-up, 10 patients in long survivor group developed a second primary tumor including two patients with second PDAC in the remaining pancreas. Conclusions: Our study showed that histopathological features such as pT and AJCC stages, lymph node metastasis, positive resection margin, lymphovascular and perineural invasion are associated with patient survival after pancreatectomy. -IPMN) and173 BD-IPMN. The majority of min-comIPMNs were incidentally found and increased cyst size on surveillance was the leading indication for resection. The median diameter of the MPD was 3mm in min-com-IPMN vs. 9mm in ex-com-IPMN (p= <.0001) and 2mm in BD-IPMN (p= <.0001). Cysts > 10mm were present in 64% of ex-com-IPMNs versus 96% of min-com-IPMNs (p= <.0001). Most signifi cantly, the vast majority of min-com-IPMN (90%) exhibited gastric-type epithelium, similar to BD-IPMN, while intestinal-type epithelium was present in 48% of ex-com-IPMNs (p= <.0001). Upon evaluating the epithelial histology of MPD vs. branch ducts in min-com-IPMN, MPD was exclusively involved by gastric-type epithelium. The main-duct components harbored lower or the same grade of dysplasia as the cystic lesion / branch-duct components and no high-grade dysplastic epithelium was seen in MPD. The overall prevalence of high-grade dysplasia (11% vs. 41%) and invasive carcinoma (6.7 % vs. 32%) was signifi cantly lower in min-com-IPMN compared to ex-com-IPMN (p<.0001). These differences were refl ected in better disease specifi c outcomes of min-com-IPMNs compared to ex-com-IPMNs (p=0.051). Conclusions: min-com-IPMN often presents with no MPD dilation and is an incidental fi nding by microscopic examination. It shares the pathological features and less aggressive biology of BD-IPMN. We propose that min-com-IPMN be categorized and treated differently than ex-com-IPMN.
1863
Proposal Conclusions: This study confi rms in a large cohort of carefully reviewed cases that the current AJCC/UICC T-stage does not have prognostic relevance, and that the individual parameters other than size used in this system are also irrelevant. The sizebased T-stage system proposed here, potentially has greater prognostic value and is more clinically relevant. B Saka, S Balci, N Dursun, P Bagci, K-T Jang, JC Roa, P Terry, I Genco, O Basturk, V Adsay. Emory, Atlanta, GA; SMC, Seoul, Korea; PUC, Santiago, Chile; UT, Knoxville, TN; MSKCC, NY, NY. Background: Various cell lineages are now being recognized in gallbladder (GB) neoplasia. There is virtually no data on the immunoprofi le of non-tumoral (fl at) dysplasia/intraepithelial-neoplasia subtypes. Design: IHC profi le of biliary-cuboidal, biliary-pencillate, gastric,  intestinal lineages of non-tumoral dysplasia was investigated and was contrasted with that of normal and other neoplastic GB. Results: Biliary markers: MUC1, absent in normal mucosa and present in 70% of invasive ca, was detected in 20% of dysplasias, mostly in the biliary-cuboidal. Gastric markers: MUC5AC  MUC6, which were commonly (62  64%) detected in normal GB mucosa, was less common (35  11%) in dysplasia, with the exception of substantial (75%) MUC5AC in gastric. Intestinal markers: While CDX2 expression was absent in normal GB mucosa (except for rare metaplastic goblet cells), its aberrant expression was detected in dysplasia; lowest (13%) in biliary-cuboidal, highest (80%) in intestinal. MUC2 also highlighted the goblet cells in most dysplasia, but not seen in non-goblet cells of dysplasia, including intestinal type. CD10, which typically formed a fairly continuous apical band in 88% of normal GB, and was very low (17%) in invasive ca, was often interrupted or lost in the dysplasias, lowest (8%) in biliary-cuboidal and highest (75%) in biliary-pencillate. CK20, absent in normal mucosa, could be expressed aberrantly in dysplasia; metaplastic (gastric and intestinal) subtypes showed CK20 in all examples, biliary ones were all negative. Biliary-pencillate type, which had overlapping histology with intestinal, more commonly expressed biliary markers (CK7:100 vs 50%; CA19-9: 75 vs 50%; CEA: 82 vs 50%), and mostly lacked intestinal ones (CK20: 0 vs 100%; CDX2: 37 vs 80%). Conclusions: Dysplasia in the GB is associated with immunophenotypic alterations different from normal, some confi rming its similarities  precursor nature to invasive carcinoma. IHC fi ndings also support the presence of different cell lineages with different profi les, albeit with overlaps, in dysplasia. Background: The pancreas does not have a capsule, its lobules are irregularly distributed, intraparenchymal adipose tissue is abundant, and the soft tissue-pancreas interface is often obscured by pancreatitis or peritumoral changes. Thus, documentation of peripancreatic soft tissue (PST) involvement (pT3 per AJCC) has been challenging and highly variable, possibly contributing to the lack of prognostic relevance for T-stage in most major studies. Design: In 250 consecutive pancreaticoduodenectomies with PDAC, fragments of soft tissue covering the pancreatic head (true PST) were examined. Briefl y, in this orangepeel approach, the soft tissue around the pancreatic head is shaved-off in 7 arbitrary regions before any sections are taken and at least 1 casette is submitted from each region even if no lymph nodes are identifi ed. Results: Carcinoma foci were identified in these orange-peeled soft tissues, in 223/250 (89%) of the cases. An additional 4.4% qualifi ed as pT3 based on extension into "adjacent" sites (duodenum/ampulla/extra-pancreatic CBD). Only 4% qualifi ed as pT1 and pT2. AJCC T-stage defi ned as such was not found to have any correlation with survival ( Figure 1 ). PST involvement often appeared as isolated solitary ducts mimicking PanINs, was not appreciated grossly, and was often identifi ed in unsuspected regions; even the anterior region, which is not routinely sampled in conventional grossing protocols, was involved in 32% of cases. The frequency of involvement of different regions was: Anterior 27.6%, anterior pancreaticoduodenal 15.3%, superior 19%, inferior 16%, posterior pancreatic 23.4%, posterior pancreaticoduodenal 19%, uncinate 57.6%. Two-thirds of the cases had >1 surfaces involved.
Immunophenotypic Characteristics and Classification of NonTumoral (Flat) Gallbladder Dysplasia
Conclusions: This study confi rms that PDACs are typically spread far beyond what meets the eye at the time of diagnosis, extending to various aspects of PST and the current defi nition of "PST involvement=pT3" allows only 4% of PDACs to truly qualify as pT1 or T2. More importantly, the current staging protocol does not correlate with prognosis. A more clinically relevant staging protocol is needed for PDAC. Background: IPNB and ICPN are characterized by intraductal (intracystic) papillary growth and have shown better outcome compared with the more common nodularsclerosing carcinoma. IPNB is a recognized precursor of invasive carcinoma, but its pathogenesis and the diagnostic criteria rather than intraductal papillary growth is ill-defi ned. They may represent a carcinogenesis pathway different from that of conventional bile duct carcinomas arising from fl at dysplasia. This study aimed to examine the clinicopathologic features and outcomes of IPNB and ICPN, and to evaluate the diagnostic criteria. Design: Fifty cases with histologic papillary features were included in this study [10 hilar, 10 intrahepatic, and 22 distal bile ducts and 11 gallbladder, M:F=30:20, median age 70 (46-86)]. Histopathologic and IHC fi ndings for mucin core (MUC) 1, 2, 5AC and 6 proteins and p53 were used to subclassify IPNBs and ICPNs. In addition, cluster analysis using MUC proteins was performed. Prognostic data with 5-year survival rate were analyzed and correlated with clinical and pathologic parameters. Results: Histopathologic examination revealed 31 pancreatobiliary, 7 gastric, 7 intestinal, and 5 oncocytic subtypes. Fifteen p53-positive cases showed poorer prognosis than those of negative cases [43% and 64%, respectively (p=0.016)]. MUC1+ cases showed poor prognosis (P=0.014). Cluster analysis using MUC proteins divided those tumors into 9 subgroups.
MUC2+MUC5+ tumors were all intestinal-type histologically; however, other groups failed to show histological correlation. According to the cluster analysis, the MUC2+MUC5+ group (5 cases) was separated from other 45 cases, and showed a tendency of better prognosis [75% and 45%, respectively (p=0. Background: Comprehensive molecular profi ling of microRNAs (miRNAs) and subsequent target gene analysis of pancreatic cancer (PaCa) can provide tumor specifi c miRNAs signatures to improve diagnostic accuracy, refi ne prognostic and predictive capabilities, and may also serve as therapeutic targets. In PaCa such a comprehensive analysis has not been reported. Design: RNA extracted from scant amounts of formalin fi xed paraffi n embedded PaCa tumor and normal pancreatic tissues were profi led for miRNA expression using microfl uidic biochip microarrays (which interrogate 2019 unique mature miRNAs).
The expression of abnormal miRNAs was then validated and quantifi ed using real time RT-PCR. Data was statistically analyzed using the Student's t-test. Survival data obtained in each case was correlated with the miRNA data using Kaplan-Meier analysis. Oncogenic potential, therapeutic modulation and downstream target genes of altered miRNA were evaluated by real time RT-PCR using PaCa cells for mRNA expression. Results: miRNA profi ling showed high expression of miR-221 in PaCa tissues compared to normal pancreas (p=0.001). These fi ndings were validated and quantifi ed using qRT-PCR (p=0.0029) ( Figure 1A ).
Survival analysis using Kaplan-Meier, demonstrated shorter survival of patients with higher expression of miR-221 compared to those with relatively lower levels of miR-221 ( kip2 and PUMA which are tumor suppressors, and found to be deregulated by over-expression or under-expression of miR-221 transfection studies in PaCa cells. These results provide molecular evidence of oncogenic potential of miR-221 in PaCa which may have a signifi cant clinical impact on prognosis  risk stratifi cation and in designing novel targeted molecular therapeutics in the future to achieve the goal of personalized and precision medicine. PDACs and 2 ACCs were also immunolabeled. Results: All 27 resected SPNs and all 8 SPN cytology samples had strong and diffuse nuclear labeling for LEF-1.The surrounding uninvolved pancreatic parenchyma in the surgical samples, including the exocrine and endocrine components, were devoid of any labeling. Similarly, both nuclear and cytoplasmic accumulation of -catenin was identifi ed in all 27 surgical SPNs and all 8 SPN cytology samples. Labeling for LEF-1 and -catenin was absent in all well-differentiated PanNETs, high-grade PanNECs, PDACs, and ACCs studied. However, nuclear LEF-1 and -catenin labeling was detected in all 4 PBs with expression ranging from 10-40% of the neoplastic cells. LEF-1 and -catenin labeling was primarily centered around and within squamoid corpuscles including tumor cells with optically clear nuclei which are known to contain biotin. Conclusions: Abnormal nuclear -catenin accumulation is accompanied by nuclear LEF-1 overexpression in both SPNs and PBs. However, in contrast to PBs, a diffuse, nuclear labeling was observed in SPNs. In conjunction with -catenin, LEF-1 is a useful ancillary stain in the diagnosis of SPNs.
Frozen Section Evaluation of Margins for Pancreatectomy
F Smith-Chakmakova, P Navarro-Alvarez, Z Yang. Penn State Hershey Medical Center, Hershey, PA. Background: Intraoperative assessment of pancreatic and bile duct margins is a routine practice for pancreatectomies in most hospital centers. However, these are diffi cult frozen sections (FS) and their misinterpretation is one of the major complaints we receive from the surgeons. As part of the quality control process, we sought to retrospectively review our performance within the last three years, in order to identify opportunities for improvement and also assess the impact on patient survival. Design: A retrospective database review was performed for all patients who underwent proximal, distal, and total pancreatectomy procedures for carcinomas from 2010 to 2013. The pathology reports and clinical information were reviewed. The original FS and permanent sections for bile duct and pancreatic margins were examined side by side.
Patient survival information was obtained from social security death index database. Results: Seventy-eight pancreatectomies cases (66 proximal, 9 distal, and 3 total) with a fi nal diagnosis of invasive carcinoma were retrieved, which included 52 cases from pancreas, 12 from ampulla, 4 from duodenum, and 5 from distal bile duct. In total there were 85 FS for pancreatic margin and 67 FS for bile duct margin. Discordance between FS versus fi nal diagnosis was seen in 15 patients (14 pancreatic carcinoma, 1 duodenal carcinoma) and all of them were positive at fi nal diagnosis. These includes 10 pancreatic margin FS (11.8%) and 5 common bile duct margin FS (7.5%), which showed no difference in the distribution of misinterpretation (Fisher's exact test, p>0.5). Of the above 15 patients, 7 had a positive uncinate margin which was not sent for frozen, and 11 had lymph node metastases. Reasons for discordance include: nondiagnostic FS due to artifact (5 cases, 33%), misinterpretation of the original FS (3 cases, 20%), tumor present on deeper levels but not on original FS (2 cases, 13%), and indeterminate (5 cases, 33%). Using Kaplan-Meier survival analysis, there was no statistical difference in disease-specifi c survival between positive and negative fi nal margin status in patients with either node-negative or node-positive pancreatic carcinoma (Logrank p>0.25). Conclusions: Our discrepancy rate in the interpretation of margins of pancreatectomy specimen during operation is well within the reported range. The most common reason of discordance was nondiagnostic FS due to artifact, followed by misinterpretation and undersampling. Although a misinterpreted margin may generate dissatisfaction from the surgeon and patients and may incur additional treatment, it does not seem to affect survival in our patient population. The former included epithelial types, and the latter included macroscopic vs. microscopic invasion, number and maximum size of invasive foci, relation to the IPMN lesion, node involvement (LNI), lymphovascular (LVI), and perineural invasion (PNI). Microscopic invasion was defi ned as <1cm of the maximal invasive component. Results: We identifi ed 40 invasive IPMNs including 22 microscopic ones. Three patterns of invasion were seen: mass-forming invasion (type 1, n=17), microscopic invasion closely associated with the main IPMN lesion (type 2, n=18), and microscopic invasion from small ducts away from the main IPMN lesion (type 3, n=5). Type 2 invasion showed foci originating from lesional (main and/or branch) ducts within the parenchyma grossly affected by IPMN, while type 3 invasion showed microscopic foci from small ducts with high-grade dysplastic epithelium, located away from the main IPMN lesion and in the background of near normal parenchyma (likely via "cancerization" of pancreatic ducts). Histopathologic features of the 3 types are shown in Table 1 Background: Pancreatic neuroendocrine tumors (PNET) are a group of neoplasms whose metastatic potential and lethality can be diffi cult to predict. We have previously reported that Raf kinase inhibitory protein (RKIP) may be a metastasis suppressor in PNET. Here, we study down-stream signaling of RKIP in both the NFkappaB (NFKB) and MAP kinase (MAPK) signaling pathways of PNET. Design: Tissue microarrays (TMAs) of PNET (n=69) were constructed from archived samples. These TMAs consisted of both primary (n=57) as well as paired and unpaired metastatic samples (n=12). TMAs were immunohistochemically stained for total NFKB (TNFKB), active NFKB (ANFKB), total MAPK (TMAPK) or active MAPK (AMAPK) and scored as strongly positive (3+), moderately positive (2+), weakly positive (1+) or negative.
Results: There were no statistically signifi cant differences in expression of TNFKB, ANFKB, TMAPK, and AMAPK between primary and metastatic PNET as seen in table 1. As illustrated in table 2, TMAPK was positively correlated with RKIP while TNFKB was inversely correlated with mitotic count. 2 ) but has signifi cant prognostic value. Accurate assessment of the mitotic rate generally requires 50 high power fi elds (HPFs) which takes signifi cant time and carries poor interobserver reproducibility. Phosphohistone H3 (PHH3) has been shown to be a specifi c marker for mitosis. This study aims to assess utility of PHH3 antibody in pancreatic WDNET. Design: Forty cases (M/F=0.8, age 20-80, median 50) of pancreatic WDNET were retrieved from the anatomic pathology archive. Immunostain for PHH3 was performed on representative tumor sections. Mitotic rate was assessed by four readers on HE and PHH3 stains. In addition, PHH3 stain was assessed in highly labeled fi elds (hotspot) on single low power (10x) and intermediate power (20x) by the senior author. Statistical analysis was performed using MedCalc version 12.7.4. Results: Based on mitotic rate on HE, there were 28 G1 and 12 G2 tumors, and mitotic rate ranged from 0 to 6.5 mitoses/2mm 2 . Intraclass correlation was 0.49 (single measure) based on the raw mitotic count. The Fleiss' kappa correlation for grade assignment was moderate (k=0.59). On PHH3 immunostain, the mitotic fi gures ranged from 0.1 to 54/2mm 2 . There is statistically signifi cant but nonlinear correlation between mitoses assessed on HE and PHH3 (p=0.0001, r=0.57). PHH3 immunostain showed improved intraclass correlation (single measure k = 0.92). In addition, there was excellent linear correlation between mitotic rate assessed on 50 HPFs and single hotspot fi eld on PHH3 immunostain (r>0.97). By Kaplan-Meier survival analysis, there was statistically signifi cant survival difference between G1 and G2 tumors as assessed on PHH3 stain (cutoff 3 mitoses/2mm 2 , p<0.0001). This cutoff (3 mitoses/2mm 2 ) corresponds to≥7/10x or >4/20x hotspot; both also showed statistically signifi cant survival difference between the two grades (p<0.0001). The Fleiss' kappa correlation for grade assigned by PHH3 is substantial (0.8). Conclusions: Mitotic rate assessed by PHH3 stain showed signifi cant correlation with mitotic rate on HE and improved interobserver reproducibility. Grading based on PHH3 of either 50 HPF or single hotspot has statistically signifi cant prognostic value, and will provide greater ease of assessment of mitotic rate in pancreatic WDNETs. Background: The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains poor, and new therapeutic approaches are critically needed. Chromosomal rearrangements in the receptor tyrosine kinase ROS1 have been reported in several neoplasms, most notably non-small cell lung carcinoma (NSCLC). However, the frequency of these rearrangements in PDAC is unknown. NSCLCs harboring ROS1 rearrangements (ROS1r) have shown off-target sensitivity to treatment with tyrosine kinase inhibitors (TKIs). Therefore, identifi cation of ROS1r in PDAC may present a novel opportunity to defi ne a new molecular target enabling responsiveness to TKI therapy. Design: Tissue microarrays were constructed from archival formalin-fi xed, paraffi nembedded tissues representing 104 PDACs and 15 non-neoplastic pancreatic controls. Anti-ROS1 immunohistochemistry was performed, and staining was scored based on intensity and percentage of positive cells. Moderate perinuclear staining in at least 50% of cells, or strong perinuclear staining in at least 10% of tumor cells, was considered positive. Comparisons between ROS1-positive and -negative groups were performed using a t-test for continuous variables and chi-square test for categorical variables. Results: Six of 104 (5.8%) PDACs were ROS1-positive. Signifi cant variables associated with ROS1 immunoreactivity included older age at the time of surgery (mean age 76.2 yrs. vs. 66.3 yrs., p=0.030), lower T stage (predominantly T2, p=0.026) Background: Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal cancers with a 5-year survival rate of 5%. Pancreatic tumor cells are adept at thriving in a microenvironment of hypoxia and poor nutrient supply. This is achieved through reprogramming of metabolic pathways and stimulating alternative sources for energy. K-RAS mutations occur in >90% of PDA and are implicated in promoting glycolytic metabolism and autophagy. However, the metabolic profi le of desmoplatic stroma accounting for the majority of PDA volume is considerably less well studied. Here we investigated determinants of glycolysis and autophagy in PDA tumor cells and stroma using a unique combination of clinical specimens and preclinical models. Design: Immunohistochemistry was performed on tissue microarrays generated from 230 PDA cases. Staining for cleaved LC3 and the monocarboxylate transporter 4 (MCT4) were employed as markers for autophagy and glycolytic metabolism respectively. For LC3, the results were scored according to staining of tumor and stromal cell percentage and were divided into three grades (1) <20% of cells, (2) 20-60% of cells and (3) >60% of cells. MCT4 staining in tumor tissue and stroma was scored as previously reported. Overall survival was calculated using the Kaplan-Meier method. Three stromal cell lines and a panel of 12 pancreatic cancer cell lines were used to assay basal autophagy, MCT4 expression, and metabolism. The effect of perturbing these processes on cell viability and apoptosis was determined. Results: As a single marker cleaved LC3 expression was not associated with overall survival (OS). High MCT4 expression was observed in PDA with shorter OS and cases with high epithelial MCT4 expression and high stromal LC3 expression had the worse prognosis. PDA cell lines and stromal cells exhibit diverse baseline autophagy and metabolic preference. However, stromal cells were particularly sensitive to the inhibition of authophagy with chloroquine. In contrast, specifi c pancreatic cancer cells were particularly sensitive to glucose withdrawal and the suppression of MCT4 expression. Conclusions: These data indicate that diverse metabolic processes supporting cell survival are activated in tumor epithelial and stromal compartments. Glycolytic metabolism within the tumor compartment is a particularly important feature of PDA, which is supplemented by effects of autophagy in the tumor microenvironment. Targeting each of these processes could represent an important therapeutic strategy for PDA. Background: Metabolic reprogramming is a hallmark of cancer and targeting tumor specifi c metabolic dependencies is an emerging therapeutic approach. Due to its genetic features (e.g. K-RAS mutations), tissue architecture, and poor vascularization pancreatic cancer (PDA) has unique metabolic requirements. While there is interest in "cutting off fuel" for PDA, recent studies indicate that there is "metabolic fl exibility" allowing cancer cells to use glucose or glutamine depending on the availability of the nutrients in the microenvironment to hinder therapeutic approaches. Therefore, targeting the excretion of "waste" (metabolic by-products from cancer cells) is of interest. In a cohort of cases, we found that PDA characterized by expression of monocarboxylate transporter 4 (MCT4) has particularly poor prognosis. MCT4 facilities export of lactate maintaining intracellular pH allowing tumors to survive in acidic conditions created by hypoxia and glycolytic metabolism. Little is known regarding the expression of MCT4 in PDA and the impact of targeting MCT4 therapeutically. Design: MCT4 expression was evaluated in the tumor and stroma compartments of 230 PDA cases. To establish if levels of MCT4 are infl uenced by the microenviroment we evaluated stromal volume and vessel microdensity (Aperio image analysis system). In parallel, targeted sequencing of PDA cases was performed to identify genetic events that were associated with expression of MCT4. Since MCT4 is involved with intracellular pH and glycolytic metabolism, MCT4 high and low expressing tumor lines were treated with glycolytic and regulators of pH. To specifi cally defi ne therapeutic vulnerabilities, a screen of 340 drugs in clinical development was carried out in models with defi ned levels of MCT4. Results: KRAS, p53, SMAD4 and mutation in DNA double strand break repair pathway were associated with high levels of MCT4 expression. Additionally, there is a correlative relationship between features of the tumor microenvironment and expression of MCT4. The knockdown of MCT4 had a profound effect on metabolism and lead to the death of PDA cells that highly express MCT4. This supports the concept that MCT4 defi nes a metabolic subtype of PDA with specifi c therapeutic vulnerabilities. In keeping with this concept, we defi ned a number of drugs that were specifi cally active against PDA models with high expression of MCT4.
MCT4 Defines a Metabolic
Conclusions: MCT4 expression is associated with specifi c genetic and microenviromental features of PDA. MCT4 defi nes a metabolic subtype of PDA with poor prognosis but vulnerabilities that can be therapeutic targets. Background: Gastrinoma is the most frequent hormonally-active neuroendocrine tumor (NET) in multiple endocrine neoplasia 1 syndrome (MEN1). It is associated with elevated fasting gastrin serum levels, recurrent peptic ulceration, and occasional diarrhea. In this study, we examined the clinicopathologic features of MEN1-associated gastrinoma. Design: Our patient population consists of 14 patients with genetically confi rmed MEN1 and hypergastrinemia who underwent surgical resection at our institution between 1980 and 2012. Immunohistochemical stain for gastrin was performed on sections from all tumor nodules in the duodenum and pancreas and all positive lymph nodes for all patients. Clinical and pathological information were retrieved from patient medical record. Results: There were 7 males and 7 females with a mean age 46.1 years (range: 24-59 years). Median preoperative fasting gastrin level was 1345 pg/mL (range, 248-7,019). Pancreaticoduodenectomy (PD) was performed in 3 patients, pylorus sparing PD was performed in 8 patients, and distal pancreatectomy was performed in 3 patients. Pancreatic NETs were identifi ed in 13 patients (93%). Pancreatic NETs were multifocal in 12 patients (86%) with a median largest tumor size of 2.1 cm (range: 0.3-6.5 cm). Duodenal NETs were identifi ed in 9/11 (82%) patients who underwent PD. Among these patients, duodenal NETs were multifocal in 6 patients with the median largest tumor size 1.0 cm (range: 0.5-2.5 cm). Peripancreatic lymph nodes were positive for NET in 92.3% patients (12/13). The median number of positive lymph nodes was 3.5 (range: 1-13). Multifocal gastric NETs were also present in all three patients who underwent PD. Duodenal and lymph node metastatic NETs were positive for gastrin in 9/9 (100%) and 12/12 patients (100%), respectively. In contrast, the pancreatic NETs were negative for gastrin in all patients and none of the gastric NETs were gastrin positive. Postoperative eugastrinemia was achieved in 86% patients (12/14) with a median follow-up of 64 months. All patients were alive with no evidence of disease except one who died from esophageal adenocarcinoma. Conclusions: Our study demonstrated that MEN1-associated gastrinomas are almost exclusively localized in the duodenum with frequent metastasis to regional lymph nodes. For patients who undergo resection for MEN1-associated gastrinoma, careful examination of the duodenum and regional lymph node dissection should be performed to achieve complete gastrinoma removal. Background: Neuroendocrine tumors of the pancreas are relatively rare neoplasms. These tumors are often sampled by endoscopic ultrasound-guided fi ne needle aspiration (FNA) which allows for cytologic evaluation and helps guide clinical management. The morphologic features of neuroendocrine differentiation can be appreciated in FNA specimens; however, the role of Ki-67 immunohistochemical (IHC) staining of cell blocks from FNAs is not well-defi ned. This study is a retrospective review of all pancreatic neuroendocrine tumors with paired FNA and surgical resection specimens identifi ed at UNC between 8/1/2003 and 9/1/2013. The goal of this study is to determine if there is correlation between the Ki-67 index of paired cytology and resection specimens from pancreatic neuroendocrine tumors. Design: A CoPath database search is performed to identify instances in which a patient underwent both FNA and subsequent surgical resection at UNC. A diagnosis of pancreatic neuroendocrine tumor in the resection specimen and the presence of a cytology cell block is required for inclusion in the study. Using these criteria, 12 paired specimens are identifi ed. Ki-67 IHC staining is performed on freshly obtained sections from the cell blocks and resections. The Ki-67 index in paucicellular cell blocks is determined by counting the total number of tumor cells present and dividing by the number of positively staining tumor cells. In more cellular specimens, up to 500 cells are evaluated. The Ki-67 index in resection specimens is determined by counting the number of tumor cells present in fi ve 40x fi elds in the area of greatest staining density and dividing by the number of positively staining tumor cells. The Ki-67 index of each cell block is compared to that of its paired resection specimen to assess for correlation. Results: Of the 12 paired specimens identifi ed, 2 are excluded due to insuffi cient material in the cell block. Ki-67 indices in the remaining 10 paired specimens show discordant results (Pearson's correlation, r=0.62, p value=0.052). Ki-67 indices in cell blocks ranged from 9.6% lower than the paired resection specimen to 5.3% higher. Nine out of 10 cell blocks demonstrated a Ki-67 index greater than 2%, placing these tumors into an intermediate grade category by WHO classifi cation. However, only 5 of the 10 resection specimens demonstrated a Ki-67 index greater than 2%. Conclusions: Ki-67 IHC staining of cell blocks from FNAs of pancreatic neuroendocrine tumors is not recommended because of a tendency to overestimate the tumor grade. RI Wu, PM Sluss, M Mino-Kenudson, WR Brugge, MB Pitman. Massachusetts General Hospital, Boston, MA. Background: Pancreatic cyst fl uid (PCF) analysis for biochemical and molecular markers provides valuable information in the pre-operative evaluation of pancreatic cysts. Due to the high vascularity of septa in serous cystadenoma (SCA), vascular endothelial growth factor (VEGF) promises to be a marker for identifying SCA in PCF. Design: PCF aspirated from patients during endoscopic ultrasound (EUS) or from resected specimens was analyzed for VEGF/Placenta Growth Factor (PlGF) heterodimer using a double-antibody enzyme-linked immunosorbent assay (ELISA) [RnD Systems (Minneapolis, MN) ]. The assay has previously been used for serum or plasma measurements and was validated for PCFs in this study. A positive result was determined to be≥60 pg/ml. True positive (TP) or false negative (FN) results were determined by histological confi rmation of SCA and false positive (FP) or true negative (TN) results with confi rmation of a non-SCA cyst by either elevated CEA above 192 ng/ml, elevated amylase above 5000 U/L, or detected KRAS mutation. Statistical analysis was performed using Fisher's exact test at 95% confi dence intervals. Results: Forty-eight PCFs were analyzed; one was technically inadequate. Of the remaining 47, only three were positive (6%): one pseudocyst, one cystic adenocarcinoma, and one SCA. Of six histologically confi rmed SCAs, only one was positive (17%). Six PCFs were nonclassifi able due to insuffi cient data, leaving 41 PCFs for performance calculations (33 TN, 5 FN, 1 TP, and 2 FP) yielding a sensitivity of 17% and specifi city of 94%. Conclusions: Analysis of PCF for VEGF by ELISA assay of VEGF/PlGF heterodimer appears to an insensitive biomarker for SCA. Although specifi city is high by calculations, there are more FP than TP results. Additional study is required to determine clinical utility. Background: Distinguishing pancreatic ductal adenocarcinoma (PDAC) from other benign pancreatic conditions, such as extensive chronic pancreatitis, can be histologically and cytologically challenging. Molecular biomarkers that have high sensitivity and specifi city for PDAC have been rigorously searched with little success. CRABP2, a retinoid acid binding protein, shuffl es retinoid acid from cytosol into the nucleus and forms a complex with nuclear retinoid acid receptor to facilitate transcriptional activities of retinoid acid. In this study, we evaluated the expression patterns of CRABP2 in surgical resection and FNA cytology specimens of PDAC. Design: Formalin-fi xed paraffi n embedded blocks from surgically resected PDAC and cell blocks of FNA pancreatic specimens were extracted from our surgical pathology and cytology archive, respectively. Polyclonal anti-CRABP2 was used and immunohistochemical staining was performed in our hospital diagnostic lab. The control groups include normal pancreatic tissue, chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) 1-3. Results: No expressions of CRABP2 were detected in normal pancreatic parenchyma, normal ductal epithelium and chronic pancreatitis. In contrast, intranuclear and cytoplasmic expression of CRABP2 was readily detected in all PDAC (50/50, 100%, Fig 1) . CRABP2 staining was also observed and progressively increased from PanIN 1 to 3 (13.9% to 88%). CRABP2 was uniformly negative (0/14) in FNA specimens if cytology diagnosis was "benign". When FNA specimens later confi rmed as PDAC by resection were evaluated, CRABP2 was positive in 55.6% (5/9) cases if cytology diagnosis was "atypia", and in 87.5% (14/16) cases if it was "malignancy". Conclusions: Our study shows that CRABP2 is highly and specifi cally expressed in PDAC, and is more commonly expressed in high-grade precursor cancerous lesions than in low-grade lesions, and suggests it may involve pancreatic carcinogenesis at earlier stage. CRABP2 could be used as a diagnostic marker to distinguish PDAC from other benign pancreatic conditions in both surgical and FNA cytology specimen. 
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